PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Mutation discovery may improve treatment for rare brain tumor type

Study findings could lead to targeted therapies for hard-to-treat craniopharyngiomas

2014-01-13
(Press-News.org) Contact information: Irene Sege
irene.sege@childrens.harvard.edu
617-919-3110
Dana-Farber Cancer Institute
Mutation discovery may improve treatment for rare brain tumor type Study findings could lead to targeted therapies for hard-to-treat craniopharyngiomas

BOSTON, Jan. 12, 2014 -- Scientists have identified a mutated gene that causes a type of tenacious, benign brain tumor that can have devastating lifelong effects. Currently, the tumor can only be treated with challenging repeated surgeries and radiation.

The discovery, reported in Nature Genetics, is encouraging, because it may be possible to attack the tumors with targeted drugs already in use for other kinds of tumors, said the investigators from Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard.

The mutated gene, known as BRAF, was found in almost all samples of tumors called papillary craniopharyngiomas. This is one of two types of craniopharyngiomas—the other being adamantinomatous—that develop in the base of the brain near the pituitary gland, hypothalamus, and optic nerves. The papillary craniopharyngiomas occur mainly in adults; adamantinomatous tumors generally affect children.

The researchers identified a different mutant gene that drives the tumors in children. Drugs that target these adamantinomatous tumors are not yet clinically available, but may be in the future, said the researchers.

"From a clinical perspective, identifying the BRAF mutation in the papillary tumors is really wonderful, because we have drugs that get into the brain and inhibit this pathway," said Sandro Santagata, MD, PhD, a co-senior author of the paper. "Previously, there were no medical treatments—only surgery and radiation—and now we may be able to go from this discovery right to a well-established drug therapy." BRAF inhibitors are currently used in treating malignant melanoma when that mutation is present.

Priscilla Brastianos, MD, co-first author of the study, and Santagata said plans are underway to design a multicenter clinical trial to investigate the efficacy of a BRAF inhibitor in patients with papillary craniopharyngiomas.

Craniopharyngiomas occur in less than one in 100,000 people. They are slow-growing tumors that don't metastasize, but they can cause severe complications, including headaches, visual impairment, hormonal imbalances, obesity and short stature. Even with expert neurosurgery, it is difficult to completely remove the tumors without damaging normal structures, and the tumors often recur.

The investigators were surprised to find that the single mutated BRAF gene was the sole driver of 95 percent of the papillary craniopharyngiomas they analyzed with whole-exome DNA sequencing. "We were really surprised to find that something as simple as a BRAF mutation by itself, rather than multiple mutations, is what drives these tumors," said Santagata.

One scenario, should the inhibitors prove successful in halting or reversing growth of the tumors, would be to test the drugs preoperatively with the aim of shrinking the tumor so less radical surgery would be needed, said Santagata.

A different mutation, in a gene called CTNNB1, was identified as the principal abnormality in the pediatric tumors, according to the report. This mutation causes overactivity in the beta-catenin molecular growth-signaling pathway. Unlike with the BRAF mutation, drugs that inhibit the CTNNB1 abnormality have not yet reached the clinic, but several groups are working on them, Santagata said.



INFORMATION:

Santagata, a pathologist, is affiliated with Dana-Farber/Boston Children's, Brigham and Women's Hospital and Harvard Medical School (HMS). Co-senior authors of the study are Mark Kieran, MD, PhD, of Dana-Farber/Boston Children's and HMS; and Gad Getz, PhD, of the Broad Institute, Massachusetts General Hospital (MGH) and HMS.

The study has three co-first authors: Brastianos of MGH, Dana-Farber Cancer Institute, HMS and the Broad; Amaro Taylor-Weiner of the Broad; and Peter Manley, MD, of Dana-Farber/Boston Children's.

The research was supported by Pedals for Pediatrics and the Clark family.

The Dana-Farber/Boston Children's Cancer and Blood Disorders Center brings together two internationally known research and teaching institutions that have provided comprehensive care for pediatric oncology and hematology patients since 1947. The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and outpatient care at the Dana-Farber Cancer Institute's Jimmy Fund Clinic. Dana-Farber/Boston Children's brings the results of its pioneering research and clinical trials to patients' bedsides through five clinical centers: the Blood Disorders Center, the Brain Tumor Center, the Hematologic Malignancies Center, the Solid Tumors Center, and the Stem Cell Transplant Center.



ELSE PRESS RELEASES FROM THIS DATE:

Non-coding DNA implicated in type 2 diabetes

2014-01-13
Non-coding DNA implicated in type 2 diabetes Variations in non-coding sections of the genome might be important contributors to type 2 diabetes risk, according to a new study. DNA sequences that don't encode proteins were once dismissed as "junk DNA", ...

Multi-institutional team finds targetable mutation in rare brain tumor

2014-01-13
Multi-institutional team finds targetable mutation in rare brain tumor BRAF mutation associated with other cancers appears to drive papillary craniopharyngiomas A team led by investigators from Massachusetts General Hospital (MGH), Brigham and Women's ...

Designer 'swiss-army-knife' molecule captures RNA in single cells in their natural tissue environment

2014-01-13
Designer 'swiss-army-knife' molecule captures RNA in single cells in their natural tissue environment Findings allow for better understanding of how tissue microenvironment affects gene expression in healthy and diseased cells PHILADELPHIA ...

Ultrasound directed to the human brain can boost sensory performance

2014-01-13
Ultrasound directed to the human brain can boost sensory performance Virginia Tech Carilion Research Institute scientists say ultrasound ranks with leading neuromodulation techniques in achieving spatial resolution Whales, bats, and even praying mantises use ultrasound as a sensory ...

Tweaking MRI to track creatine may spot heart problems earlier, Penn Medicine study suggests

2014-01-13
Tweaking MRI to track creatine may spot heart problems earlier, Penn Medicine study suggests Measuring creatine levels with MRI has benefits over contrast-enhanced MRI and MRS PHILADELPHIA— A new MRI method to map creatine at higher ...

Study: At-home test can spot early Alzheimer's

2014-01-13
Study: At-home test can spot early Alzheimer's Finding symptoms early is crucial to treatment, at-home paper test can help COLUMBUS, Ohio – The Self-Administered Gerocognitive Examination (SAGE test), which takes less than 15 minutes ...

School drug tests don't work, but 'positive climate' might

2014-01-13
School drug tests don't work, but 'positive climate' might PISCATAWAY, NJ – School drug testing does not deter teenagers from smoking marijuana, but creating a "positive school climate" just might, according to research reported in the ...

Brief mental training sessions have long-lasting benefits for seniors' cognition and everyday function

2014-01-13
Brief mental training sessions have long-lasting benefits for seniors' cognition and everyday function Older adults who received as few as 10 sessions of mental (cognitive) training showed improvements in reasoning ability and speed-of-processing when compared with untrained ...

Advanced radiation therapy for head and neck cancer may be better than traditional radiation at preventing side effects and cancer recurrence

2014-01-13
Advanced radiation therapy for head and neck cancer may be better than traditional radiation at preventing side effects and cancer recurrence Patients with head and neck cancer who are treated with an advanced form of radiation therapy may experience fewer side effects and ...

Study finds more targeted form of radiation improves survival in patients with head and neck cancers

2014-01-13
Study finds more targeted form of radiation improves survival in patients with head and neck cancers IMRT reduces side effects, also improves outcomes HOUSTON — Patients with cancers of the head and neck who received intensity-modulated ...

LAST 30 PRESS RELEASES:

Cercus electric stimulation enables cockroach with trajectory control and spatial cognition training

Day-long conference addresses difficult to diagnose lung disease

First-ever cardiogenic shock academy features simulation lab

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

[Press-News.org] Mutation discovery may improve treatment for rare brain tumor type
Study findings could lead to targeted therapies for hard-to-treat craniopharyngiomas